December 23, 2024- Cardinal Health announced the start of weekly production of actinium-225 (Ac-225) through its Center for Theranostics Advancement in Indianapolis, Indiana, in collaboration with TerraPower Isotopes. The routine production will increase the availability of Ac-225 for the manufacturing of investigational therapeutic drug products and provide for the future commercial manufacturing of novel therapies that will help advance patient care.
Ac-225 is an alpha-emitting radionuclide that can be attached to small molecules, peptides or antibodies known to target cancerous cells. These drug products are currently being evaluated through worldwide clinical studies as targeted alpha therapies (TATs) for some of the most commonly diagnosed cancers, including prostate, neuroendocrine, breast, colon, melanoma and lymphoma.
Cardinal Health’s investments in its Center for Theranostics Advancement have supported the growth of theranostics globally, as the company works with pharmaceutical innovators across their product lifecycles, from concept to commercialization. Growth of the Center for Theranostics Advancement has enabled the company to create strategic collaborations with pharmaceutical manufacturers to support the development and commercialization of new precision medicines as well as the growing demand for cGMP Ac-225.